CELG Celgene Corporation

68.2
-1.54  -2%
Previous Close 69.74
Open 68.91
Price To Book 9.81
Market Cap 47688975488
Shares 699,251,840
Volume 5,244,606
Short Ratio
Av. Daily Volume 6,512,945

SEC filingsSee all SEC filings

  1. 8-K - Current report 181156960
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181139602
  3. 8-K - Current report 181137637
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18972348
  5. 8-K - Current report 18970196

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data at ASH 2018 noted at lowest dose ORR 79%; CR 43%.
JCARH125 - EVOLVE
Multiple myeloma
Phase 1b initiated.
JCAR017 in combination with durvalumab - PLATFORM
Non-hodgkin Lymphoma
Phase 2b trial initiated 3Q 2017.
CC-220
Systemic lupus erythematosus (SLE)
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 session at ASCO June 2018.
Luspatercept
Myelofibrosis
Phase 3 primary endpoint met - October 8, 2018.
OTEZLA
Scalp Psoriasis
Phase 3 data released December 21, 2017 - co-primary endpoints not met.
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
Phase 3 data released at ASH 2016.
REVLIMID - REMARC
Maintenance in Patients with Diffuse large B-cell lymphoma (DLBCL) responding to R-CHOP to induction therapy
Phase 3 data released at ASH December 2016.
REVLIMID - MYELOMA XI
Induction and Maintenance in ASCT Eligible
Phase 3 enrollment complete - noted April 27, 2017.
REVLIMID - MM-026 ARUMM
Multiple Myeloma - Maintenance Post-VMP induction
Phase 3 data released at ASH 2016.
REVLIMID - CLL-002 CONTINUUM
Maintenance in Second-line Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due 2020.
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
Phase 3 data released February 6, 2018 - primary endpoint (PFS) met. Presentation at ASCO June 1, 2018 noted PFS of 11.2 months vs. 7.1 months.
MM-007 OPTIMISMM
Multiple Myeloma - refractory
Phase 3 data released July 23, 2018. Primary endpoint met. Regulatory filing due 1Q 2019. PFS 39.4 months.
REVLIMID - AUGMENT
Relapsed or Refractory Follicular Lymphoma
Phase 3 enrolling. Enrollment to be completed mid-2019.
Ozanimod - TRUE NORTH
Ulcerative Colitis
Phase 3 - primary endpoint met.
OTEZLA - PSA-006
Psoriatic Arthritis
sNDA filing due 2017
OTEZLA
Once daily formulation
Phase 3 trial met endpoint.
OTEZLA - RELIEF
Behçet’s Disease
Phase 3 primary and key secondary endpoints met. Response rate 21.4% vs 4.5% for placebo. Regulatory filing 1H 2019.
Luspatercept - BELIEVE
b -thalassemia
Phase 3 trial met primary endpoint - June 28, 2018. Data to presented at ASH December 2018 noted red blood cell transfusion independence 38% v 13% for placebo. Regulatory filing due 1H 2019.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 trial will not be initiated - noted October 19, 2017.
GED-0301 (CD-003)
Crohn’s disease
Phase 3 trial to discontinue due to lack of efficacy - noted October 19, 2017.
GED-0301 (CD-002)
Crohn’s disease
Phase 3 data due 4Q 2018.
Oral Azacitidine - CC-486-AML-001
Post induction AML Maintenance
Phase 3 data due 4Q 2018.
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 enrolling.
CC-486 (Oral Azacitidine)
Low risk/INT-1 transfusion-dependent MDS
Phase 3 data released June 2017 - met the endpoint of a pre-planned interim futility analysis.
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
Refusal-to-file letter issued February 27, 2018. NDA to be refiled 1Q 2019.
Ozanimod - RADIANCE
Relapsing Multiple Sclerosis
Phase 3 trial to be initiated 2018.
OTEZLA
Ulcerative Colitis
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 3 trial planned for 2018.
Marizomib
Glioblastoma (GBM) cancer
Phase 1/2 MM trials placed on clinical hold - September 7, 2017. AML/MDS trials to continue.
Durvalumab - FUSION
Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML
Approved February 22, 2017.
REVLIMID
Multiple myeloma (MM) - autologous stem cell transplant (ASCT)
Phase 2 pivotal trial completion of enrolment announced November 27, 2018. Data likely in 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 1 data presented at ASCO 2018. 49% ORR, 46% CR at 6 months.
Lico-cel (CD-19 JCAR017) - TRANSCEND
r/r B cell non-Hodgkin lymphoma - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 1/2 ongoing
JCAR014
Adults with advanced B cell malignancies
Phase 3 data due released Feb 17, 2017 - primary endpoint met, disability endpoint not met. Full data released October 27, 2017 at ECTRIMS meeting.
Ozanimod - SUNBEAM
Relapsing Multiple Sclerosis
Pivotal program to be initiated 2018.
CC-122
Non-Hodgkin Lymphoma
Phase 3 trial initiated 4Q 2017.
Ozanimod
Crohn's disease
Phase 3 data due 4Q 2018.
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 1 data at ASH noted 81% ORR; 43% CR.
Liso-cel (JCAR017) - TRANSCEND CLL-004
Chronic Lymphocytic Leukemia (CLL)
Pivotal trial completed enrollment April 2018.
liso-cel (JCAR017) - TRANSCEND NHL-001
Non-Hodgkin Lymphoma
Phase 1 initial data at ASH December 2, 2018 noted 83% ORR.
bb21217
Multiple Myeloma

SEC Filings

  1. 8-K - Current report 181156960
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181139602
  3. 8-K - Current report 181137637
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 18972348
  5. 8-K - Current report 18970196
  6. 8-K - Current report 18945375
  7. 8-K - Current report 18940632
  8. 8-K - Current report 18926284
  9. 8-K - Current report 18907664
  10. 8-K - Current report 18896900